The Slow Pandemic

The last two pharmaceutical companies that received approval from the FDA (before the pandemic) to produce new antibiotics - one went bankrupt and the other got sold off. There is little financial incentive to research or produce these drugs. Researcher Lori Burrows talks to us about new supply models that could re-ignite research in this area.

Globally, we are quickly running out of antibiotic solutions to fight both common and high-risk bacterial infections. Bacteria are becoming increasingly resistant to over-used antibiotics, and it
is no longer financially viable for pharmaceutical companies to invest in the research and development of new antibiotics. The WHO and UN have prioritized this problem. What does this mean for vulnerable patients, and can prevention help?

The phone call no parent ever wants to receive… Hear how Seana and her husband went through the harrowing first 14 months of her daughter Kiera’s illness before receiving a proper diagnosis, her 18-month stay in hospital and all the care, logistics and education that come with living with a child who requires an IV catheter connected to her heart, and how one solution is
helping these parents reduce their fears that their child’s lifeline could be deadly.